Amphastar Pharmaceuticals Inc
AMPH27.120USD
+0.310+1.16%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.26BMarket Cap
11.50P/E TTM
More Details of Amphastar Pharmaceuticals Inc Company
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Amphastar Pharmaceuticals Inc Info
Ticker SymbolAMPH
Company nameAmphastar Pharmaceuticals Inc
IPO dateJun 25, 2014
CEOZhang (Yongfeng Yongfeng)
Number of employees2028
Security typeOrdinary Share
Fiscal year-endJun 25
Address11570 6th St
CityRANCHO CUCAMONGA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91730
Phone19099809484
Websitehttps://amphastar.com/
Ticker SymbolAMPH
IPO dateJun 25, 2014
CEOZhang (Yongfeng Yongfeng)
Company Executives of Amphastar Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
72.45K
-0.69%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
--
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
167.00M
95.75%
France
7.11M
4.08%
China
299.00K
0.17%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
Other
58.80%
Shareholders
Shareholders
Proportion
Applied Physics & Chemistry Laboratories, Inc.
14.86%
BlackRock Institutional Trust Company, N.A.
10.75%
Zhang (Jack Yongfeng)
5.71%
The Vanguard Group, Inc.
5.68%
TD Asset Management Inc.
4.20%
Other
58.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.55%
Investment Advisor/Hedge Fund
22.63%
Corporation
14.86%
Individual Investor
9.43%
Hedge Fund
6.47%
Research Firm
2.82%
Pension Fund
1.06%
Bank and Trust
0.34%
Sovereign Wealth Fund
0.12%
Other
1.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
586
33.97M
85.20%
+16.67K
2025Q3
603
33.96M
84.80%
+202.84K
2025Q2
607
33.74M
83.87%
-544.61K
2025Q1
597
34.53M
80.40%
-3.80M
2024Q4
593
35.69M
79.40%
-112.11K
2024Q3
575
35.68M
75.48%
+965.70K
2024Q2
565
34.64M
73.86%
+833.26K
2024Q1
548
33.97M
73.49%
-1.92M
2023Q4
531
33.91M
72.12%
+1.03M
2023Q3
499
32.97M
71.03%
+509.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
11.02%
-399.35K
-7.23%
Jun 30, 2025
Zhang (Jack Yongfeng)
2.62M
5.64%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.67M
5.73%
+251.01K
+10.40%
Jun 30, 2025
TD Asset Management Inc.
2.03M
4.38%
-177.21K
-8.01%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.63M
3.5%
+270.52K
+19.94%
Jun 30, 2025
State Street Investment Management (US)
1.58M
3.39%
-28.38K
-1.77%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.72%
+174.00
+0.01%
Jun 30, 2025
Boston Trust Walden Company
1.18M
2.53%
-39.17K
-3.22%
Jun 30, 2025
Epoch Investment Partners, Inc.
1.24M
2.67%
-19.94K
-1.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.25%
State Street SPDR S&P Pharmaceuticals ETF
1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.38%
Invesco S&P SmallCap 600 GARP ETF
1.12%
Acquirers Small and Micro Deep Value ETF
0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.77%
Invesco S&P SmallCap Health Care ETF
0.56%
First Trust Small Cap Value AlphaDEX Fund
0.5%
Distillate Small/Mid Cash Flow ETF
0.45%
VictoryShares Small Cap Free Cash Flow ETF
0.37%
View more
Invesco Pharmaceuticals ETF
Proportion2.25%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.38%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.12%
Acquirers Small and Micro Deep Value ETF
Proportion0.87%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion0.77%
Invesco S&P SmallCap Health Care ETF
Proportion0.56%
First Trust Small Cap Value AlphaDEX Fund
Proportion0.5%
Distillate Small/Mid Cash Flow ETF
Proportion0.45%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.37%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Amphastar Pharmaceuticals Inc?
The top five shareholders of Amphastar Pharmaceuticals Inc are:
Applied Physics & Chemistry Laboratories, Inc. holds 6.83M shares, accounting for 14.68% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.12M shares, accounting for 11.02% of the total shares.
Zhang (Jack Yongfeng) holds 2.62M shares, accounting for 5.64% of the total shares.
The Vanguard Group, Inc. holds 2.67M shares, accounting for 5.73% of the total shares.
TD Asset Management Inc. holds 2.03M shares, accounting for 4.38% of the total shares.
Applied Physics & Chemistry Laboratories, Inc. holds 6.83M shares, accounting for 14.68% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.12M shares, accounting for 11.02% of the total shares.
Zhang (Jack Yongfeng) holds 2.62M shares, accounting for 5.64% of the total shares.
The Vanguard Group, Inc. holds 2.67M shares, accounting for 5.73% of the total shares.
TD Asset Management Inc. holds 2.03M shares, accounting for 4.38% of the total shares.
What are the top three shareholder types of Amphastar Pharmaceuticals Inc?
The top three shareholder types of Amphastar Pharmaceuticals Inc are:
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
Applied Physics & Chemistry Laboratories, Inc.
BlackRock Institutional Trust Company, N.A.
Zhang (Jack Yongfeng)
How many institutions hold shares of Amphastar Pharmaceuticals Inc (AMPH)?
As of 2025Q4, 586 institutions hold shares of Amphastar Pharmaceuticals Inc, with a combined market value of approximately 33.97M, accounting for 85.20% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.40%.
What is the biggest source of revenue for Amphastar Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Amphastar Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
